Therapeutic Benefit of Baseline PSA
September 11, 2013
Therapeutic Benefit of Baseline PSA: Lower Baseline PSA is Associated with a Greater Overall Survival Benefit from Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
Dr. Leonard Gomella discusses an important topic that has been further defined based on the registration trial for sipuleucel-T, namely the therapeutic benefit that is seen in patients based on baseline PSA.
Click HERE to read an exclusive report by a UroToday medical writer